- Datum05.05.2026
- Uhrzeit12:00 - 13:00 Uhr
- Veranstalter
stock3
FibroGen Inc. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| L&S | VK | |||||
| Tradegate BSX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-2,48 %
Intraday
-0,70 %
1 Woche
1,14 %
1 Monat
-19,25 %
Seit Jahresbeginn
-14,94 %
1 Jahr
-98,30 %
3 Jahre
-98,71 %
5 Jahre
-98,35 %
10 Jahre
Passender Service zu FibroGen Inc.
Webinar zu FibroGen Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,850-12,600
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von FibroGen Inc.
Keine Dividenden verfügbar
Termine von FibroGen Inc.
- Mai11FibroGen Inc.Q1 2026 Earnings Release
- Aug10FibroGen Inc.Q2 2026 Earnings Release
- Nov9FibroGen Inc.Q3 2026 Earnings Release
Beschreibung
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
